申请人:Otsuka Pharmaceutical Co., Ltd.
公开号:US04147869A1
公开(公告)日:1979-04-03
3,4-Dihydrocarbostyril derivatives represented by the formula (I) ##STR1## wherein R.sub.1 represents an alkylcarbonyl group, a cycloalkylcarbonyl group, an alkylsulfonyl group, a phenylsulfonyl group, a carbamoyl group or an alkoxycarbonyl group, R.sub.2 and R.sub.3, which may be the same or different, each represents a hydrogen atom, an alkyl group, a phenylalkyl group or a phenoxyalkyl group, or R.sub.2 and R.sub.3 can form, when taken together with the nitrogen atom to which they are attached, a heterocyclic group selected from the group consisting of piperidino, pyrrolidino, morpholino and 1-piperazinyl which may be substituted with a phenyl group or an alkyl group having 1 to 4 carbon atoms, with the proviso that, when the group --NHR.sub.1 is attached to the 8-position of the 3,4-dihydrocarbostyril nucleus in which R.sub.1 represents an alkylcarbonyl group and one of R.sub.2 and R.sub.3 represents a hydrogen atom, then the other group of R.sub.2 and R.sub.3 cannot be an alkyl group, pharmaceutically acceptable acid addition salts thereof, and process for preparing the same.
3,4-二氢基咔波斯蒂尔衍生物的化学式(I)如下:其中R.sub.1代表一个烷基羰基、一个环烷基羰基、一个烷基磺酰基、一个苯基磺酰基、一个氨基甲酰基或一个烷氧羰基,R.sub.2和R.sub.3,可以相同也可以不同,分别代表一个氢原子、一个烷基、一个苯基烷基或一个苯氧基烷基,或者R.sub.2和R.sub.3可以与它们连接的氮原子一起形成一个异环烷基,选择自哌啶基、吡咯啶基、吗啉基和1-哌嗪基,这些基可能被苯基或者含有1至4个碳原子的烷基取代,但是要注意的是,当基团--NHR.sub.1连接到3,4-二氢基咔波斯蒂尔核的8位,其中R.sub.1代表一个烷基羰基,R.sub.2和R.sub.3中的一个代表氢原子时,另一个R.sub.2和R.sub.3不能是烷基,其药用可接受酸盐以及其制备方法。